[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"point-of-care-sti-testing\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:point-of-care-sti-testing":82},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":26,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100580956",false,"NCT06844045","Point of Care STI Testing","Clinical and Implementation Outcomes of a Point of Care Sexually Transmitted Infection Testing Strategy to Improve HIV Prevention Service Delivery in Adolescents","Inclusion Criteria:\n\n\\- Patients age 16-24 years receiving POCT or lab-based GC\u002FCT testing\n\nExclusion Criteria:\n\n\\- Patients with known HIV or active PrEP prescriptions.","ALL","16 Years","24 Years",{"count":19,"type":20},6460,"ESTIMATED","INTERVENTIONAL",[23],"NA","The proposed research hypothesizes that point-of-care testing (POCT) for sexually transmitted infections (STIs) gonorrhea and chlamydia will be a feasible, acceptable, and appropriate implementation strategy for improving HIV testing and Pre-exposure prophylaxis (PrEP) delivery in youth, by increasing opportunities for clinician-patient counseling, decreasing loss to follow up, and allowing for same-day HIV prevention service provision. This hypothesis will be tested in a pragmatic non-randomized trial comparing clinical (HIV testing and PrEP counseling and prescription) and implementation (feasibility, acceptability, and appropriateness) outcomes between adolescents receiving POCT compared to laboratory-based testing at three clinics within a large pediatric health system.",[12],[27,28,29,30,31,32],"HIV Prevention","HIV Testing","HIV Pre-Exposure Prophylaxis","Gonorrhea","Chlamydia","Sexually Transmitted Infections","RECRUITING","2026-04-29",{"date":36,"type":37},"2026-05-05","ACTUAL",{"date":39,"type":37},"2026-02-24",{"date":41,"type":20},"2026-12-31",{"name":43,"class":44},"Icahn School of Medicine at Mount Sinai","OTHER",1,{"id":47,"slug":4,"hasResults":10,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":54,"minAge":4,"maxAge":4,"enrollmentInfo":55,"targetDuration":57,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":68,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":4},"100622850","NCT07388979","MAGIA H3S Point of Care Test Performance for HIV, HBV, HCV, and Syphilis Screening in Pregnant Women in DR Congo","MAGIa In-vitro- Diagnostics Medical Device Dedicated to Combined Screening of HIV, HBV, HCV and Syphilis and HBV Reflective Panels aMong Congolese pregnAnt woMen Attending to Ante Natal Care Consultations","MAGICS MAM","Inclusion Criteria:\n\n* Being pregnant, regardless of age or stage of pregnancy (prenatal period);\n* Having signed an informed consent form at the start of prenatal care (CPN) to participate in the study.\n\nNote: for pregnant minors, the consent of a parent or legal guardian is required;\n\n* Have chosen to attend prenatal care at the healthcare facility selected for the study;\n* Plan to give birth at the same healthcare facility where they were included in the study;\n* Plan to attend postnatal care (PNC) and preschool consultations (PSC) at the same healthcare facility where they were included in the study.\n* Plan to give birth at the same health facility where they were enrolled;\n* Plan to attend postnatal consultations (PNC) and preschool consultations (PSC) at the same facility\n\nExclusion Criteria:\n\n* Women in labor or who refuse to give their consent.",true,"FEMALE",{"count":56,"type":20},7500,"12 Months","OBSERVATIONAL","Performance study to evaluate the clinical performance of the In-Vitro Diagnostic Medical Device MagIA H3S (a Multiplex Point-of-Care test for the combined detection of Human Immunodeficiency Virus (HIV), Hepatitis B and C and Syphilis) from pregnant women attending antenatal care (ANC) services in the Democratic Republic of the Congo. This study aligns with the WHO 2022-2030 strategy for the integrated elimination of mother-to-child transmission of HIV, HBV, HCV, and syphilis.",[61,62,63,64,65,66,12,67],"HIV - Human Immunodeficiency Virus","HBV (Hepatitis B Virus)","Hepatitis C Virus (HCV)","Syphilis","Mother-to-Child Transmission","Performance","TREAT B",[69,70,71],"Triple elimination","Mother-to-child transmission","Democratic republic of the Congo","NOT_YET_RECRUITING","2026-01-28",{"date":75,"type":37},"2026-02-05",{"date":77,"type":20},"2026-03-01",{"date":79,"type":20},"2027-12-21",{"name":81,"class":44},"Gardiens de Vies",""]